Administrative Core and Senior Leadership - Project Summary/Abstract The Cold Spring Harbor Laboratory Cancer Center is led by Bruce Stillman, Ph.D. (Gene Regulation and Cell Proliferation Program), David Tuveson, M.D., Ph.D. (Signal Transduction Program), Nicholas Tonks, Ph.D. (Signal Transduction Program), and Denise Roberts, Ph.D. (Administration). Stillman has been the Director of the CSHL Cancer Center since 1992, while concurrently holding the position of President of Cold Spring Harbor Laboratory. As Director, he is responsible for the overall direction, planning and fundraising to support cancer research and the Shared Resources. He is assisted in oversight of the Cancer Center by three Deputy Directors: Tuveson, Tonks, and Roberts. Tuveson, Deputy Director for Programs, is primarily responsible for oversight of the cancer research Programs and recruitment of new members to the Cancer Center. Tonks, Deputy Director for Shared Resources, supervises all the Shared Resource leaders, acts as a liaison between faculty, scientific staff and Shared Resource personnel, and provides leadership to maintain the highest quality scientific services. Roberts, Deputy Director for Administration, coordinates all administrative services on behalf of the Cancer Center, coordinates the Executive Committee of the Cancer Center and, with Tonks, oversees the Shared Resources. These four senior leaders are committed to maintaining and continually improving CSHL as a premier center for cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA045508-32
Application #
9773896
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
32
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129
Forcier, Talitha L; Ayaz, Andalus; Gill, Manraj S et al. (2018) Measuring cis-regulatory energetics in living cells using allelic manifolds. Elife 7:
Naguib, Adam; Mathew, Grinu; Reczek, Colleen R et al. (2018) Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells. Cell Rep 23:58-67
Aberle, M R; Burkhart, R A; Tiriac, H et al. (2018) Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg 105:e48-e60
Bhagwat, Anand S; Lu, Bin; Vakoc, Christopher R (2018) Enhancer dysfunction in leukemia. Blood 131:1795-1804
Khan, Jalal A; Maki, Robert G; Ravi, Vinod (2018) Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. J Clin Oncol 36:194-201
Chen, Wei-Chia; Tareen, Ammar; Kinney, Justin B (2018) Density Estimation on Small Data Sets. Phys Rev Lett 121:160605
Cheng, Derek; Tuveson, David (2018) Kras in Organoids. Cold Spring Harb Perspect Med 8:
Albrengues, Jean; Shields, Mario A; Ng, David et al. (2018) Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361:
Cook, Natalie; Basu, Bristi; Smith, Donna-Michelle et al. (2018) A phase I trial of the ?-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer 118:793-801

Showing the most recent 10 out of 380 publications